- Home
- DCTH vs MRVI Comparison
DCTH vs MRVI Comparison
Compare DCTH & MRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DCTH
- MRVI
- Stock Information
- Founded
- DCTH 1988
- MRVI 2014
- Country
- DCTH United States
- MRVI United States
- Employees
- DCTH N/A
- MRVI N/A
- Industry
- DCTH Medical/Dental Instruments
- MRVI Biotechnology: Pharmaceutical Preparations
- Sector
- DCTH Health Care
- MRVI Health Care
- Exchange
- DCTH Nasdaq
- MRVI Nasdaq
- Market Cap
- DCTH 388.3M
- MRVI 376.2M
- IPO Year
- DCTH N/A
- MRVI 2020
- Fundamental
- Price
- DCTH $11.75
- MRVI $2.88
- Analyst Decision
- DCTH Strong Buy
- MRVI Hold
- Analyst Count
- DCTH 4
- MRVI 9
- Target Price
- DCTH $24.50
- MRVI $5.25
- AVG Volume (30 Days)
- DCTH 497.8K
- MRVI 967.6K
- Earning Date
- DCTH 11-07-2025
- MRVI 11-06-2025
- Dividend Yield
- DCTH N/A
- MRVI N/A
- EPS Growth
- DCTH N/A
- MRVI N/A
- EPS
- DCTH 0.06
- MRVI N/A
- Revenue
- DCTH $70,240,000.00
- MRVI $219,830,000.00
- Revenue This Year
- DCTH $159.22
- MRVI N/A
- Revenue Next Year
- DCTH $42.78
- MRVI $7.23
- P/E Ratio
- DCTH $211.26
- MRVI N/A
- Revenue Growth
- DCTH 491.35
- MRVI N/A
- 52 Week Low
- DCTH $8.08
- MRVI $1.67
- 52 Week High
- DCTH $18.23
- MRVI $9.50
- Technical
- Relative Strength Index (RSI)
- DCTH 59.13
- MRVI 62.30
- Support Level
- DCTH $10.61
- MRVI $2.61
- Resistance Level
- DCTH $11.38
- MRVI $2.98
- Average True Range (ATR)
- DCTH 0.49
- MRVI 0.17
- MACD
- DCTH 0.06
- MRVI 0.04
- Stochastic Oscillator
- DCTH 79.61
- MRVI 86.23
About DCTH Delcath Systems Inc.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.
About MRVI Maravai LifeSciences Holdings Inc.
Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.